Pharmaceutical composition containing pyridylaminoacetic acid compound
The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
1. A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof and a nonionic surfactant, which further comprises edetic acid or a salt thereof,
wherein the nonionic surfactant includes polyoxyethylene sorbitan fatty acid ester.
2. The pharmaceutical composition according to claim 1 , wherein the polyoxyethylene sorbitan fatty acid ester includes polyoxyethylene sorbitan fatty acid ester selected from the group consisting of Polysorbate 80, Polysorbate 60, Polysorbate 40, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan trioleate, and Polysorbate 65.
3. The pharmaceutical composition according to claim 1 , wherein the content of the nonionic surfactant is in a range of 0.001 to 5% (w/v).
4. The pharmaceutical composition according to claim 3 , wherein the content of the nonionic surfactant is in a range of 0.5 to 3% (w/v).
5. The pharmaceutical composition according to claim 1 , wherein the content of the nonionic surfactant is in a range of 1 to 20,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.
6. The pharmaceutical composition according to claim 1 , wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.0001 to 0.1% (w/v).
7. The pharmaceutical composition according to claim 6 , wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.001 to 0.003% (w/v).
8. The pharmaceutical composition according to claim 1 , wherein the content of edetic acid or a salt thereof is in a range of 0.001 to 1% (w/v).
9. The pharmaceutical composition according to claim 8 , wherein the content of edetic acid or a salt thereof is in a range of 0.01 to 0.1% (w/v).
10. The pharmaceutical composition according to claim 1 , wherein the content of edetic acid or a salt thereof is in a range of 3 to 1,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.
11. The pharmaceutical composition according to claim 1 , which further comprises boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof.
12. The pharmaceutical composition according to claim 1 , which does not comprise sorbic acid.
13. The pharmaceutical composition according to claim 1 , which is filled into a container made of polyethylene.
14. The pharmaceutical composition according to claim 1 , for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.